Literature DB >> 26209222

Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia.

Sarah N Forrester1, Joseph J Gallo2, Gwenn S Smith3, Jeannie-Marie S Leoutsakos3.   

Abstract

OBJECTIVE: To identify clusters of patients with incident mild cognitive impairment (MCI) based on their neuropsychiatric symptoms (NPS) and to examine the risk of progression to dementia based on these clusters.
METHODS: In this cohort study with a median of 2 years of follow-up from the National Alzheimer's Coordinating Center, 540 patients with MCI at least 60 years old with complete data and follow-up were studied. Latent class analysis was used to identify clusters of patients based on their NPS, and Cox proportional hazards models were used to examine risk of progression to dementia based on clusters. Incident MCI was defined as a participant having MCI at a current visit but having been cognitively normal at his or her previous (yearly) visit. The Neuropsychiatric Inventory Questionnaire assessed the presence of 12 neuropsychiatric behavioral domains.
RESULTS: Three clusters were identified: a severe cluster (agitation, anxiety, apathy, nighttime behaviors, inhibition), an affective cluster (depression, anxiety, irritability, nighttime behaviors), and an asymptomatic cluster. The prevalence of each class was 56% for the asymptomatic class followed by the affective class (37%) and finally the severe class (7%). Compared with the asymptomatic class, the severe class had more than twice the hazard of progression to dementia (2.69; 95% CI: 1.12-2.70) and the affective class had over 1.5 times the hazard of progression to dementia (1.79; 95% CI: 1.12-2.70).
CONCLUSION: Among persons with incident MCI, patterns of NPS may increase the likelihood of progression to dementia. Implications for early detection and treatment are discussed.
Copyright © 2016 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MCI; dementia; neuropsychiatric symptoms

Mesh:

Year:  2015        PMID: 26209222      PMCID: PMC4646727          DOI: 10.1016/j.jagp.2015.05.007

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  31 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction.

Authors:  Paul B Rosenberg; Michelle M Mielke; Brian Appleby; Esther Oh; Jeannie-Marie Leoutsakos; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2010-09-15       Impact factor: 3.485

3.  Psychiatric symptomatology and prodromal Alzheimer's disease.

Authors:  Maura P Copeland; Ella Daly; Virginia Hines; Carol Mastromauro; Deborah Zaitchik; Jeanette Gunther; Marilyn Albert
Journal:  Alzheimer Dis Assoc Disord       Date:  2003 Jan-Mar       Impact factor: 2.703

Review 4.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

Review 5.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

Authors:  G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Syndromes of behavioural and psychological symptoms in mild Alzheimer's disease.

Authors:  Maria Moran; C Walsh; A Lynch; R F Coen; D Coakley; B A Lawlor
Journal:  Int J Geriatr Psychiatry       Date:  2004-04       Impact factor: 3.485

10.  The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach.

Authors:  E Hogervorst; S Bandelow; M Combrinck; S R Irani; S Irani; A D Smith
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

View more
  16 in total

1.  Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the ADNI Cohort.

Authors:  Adam P Mecca; Hannah R Michalak; Julia W McDonald; Emily C Kemp; Erika A Pugh; Melinda L Becker; Marcia C Mecca; Christopher H van Dyck
Journal:  Dement Geriatr Cogn Disord       Date:  2018-06-08       Impact factor: 2.959

2.  Neuropsychiatric Symptoms and the Diagnostic Stability of Mild Cognitive Impairment.

Authors:  Michael A Sugarman; Michael L Alosco; Yorghos Tripodis; Eric G Steinberg; Robert A Stern
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Trajectories of neuropsychiatric symptoms over time in healthy volunteers and risk of MCI and dementia.

Authors:  Jeannie-Marie S Leoutsakos; Elizabeth A Wise; Constantine G Lyketsos; Gwenn S Smith
Journal:  Int J Geriatr Psychiatry       Date:  2019-09-02       Impact factor: 3.485

4.  [Diethylhexyl phthalate induces anxiety-like behavior and learning and memory impairment in mice probably by damaging blood-brain barrier].

Authors:  F Li; Y Zhu; X Sun; H Hu; M Zhou; Y Bai; H Hu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

5.  Examining differences in neuropsychiatric symptom factor trajectories in empirically derived mild cognitive impairment subtypes.

Authors:  Alyssa N De Vito; Matthew Calamia; Daniel S Weitzner; John P K Bernstein
Journal:  Int J Geriatr Psychiatry       Date:  2018-10-01       Impact factor: 3.485

6.  Characterisation of Physical Frailty and Associated Physical and Functional Impairments in Mild Cognitive Impairment.

Authors:  Ma Shwe Zin Nyunt; Chang Yuan Soh; Qi Gao; Xinyi Gwee; Audrey S L Ling; Wee Shiong Lim; Tih Shih Lee; Philip L K Yap; Keng Bee Yap; Tze Pin Ng
Journal:  Front Med (Lausanne)       Date:  2017-12-18

7.  Frontal White Matter Hyperintensity Is Associated with Verbal Aggressiveness in Elderly Women with Alzheimer Disease and Amnestic Mild Cognitive Impairment.

Authors:  Noriko Ogama; Takashi Sakurai; Naoki Saji; Toshiharu Nakai; Shumpei Niida; Kenji Toba; Hiroyuki Umegaki; Masafumi Kuzuya
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2018-04-11

8.  Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers.

Authors:  Elizabeth A Wise; Paul B Rosenberg; Constantine G Lyketsos; Jeannie-Marie Leoutsakos
Journal:  Alzheimers Dement (Amst)       Date:  2019-04-18

9.  Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging.

Authors:  Janina Krell-Roesch; Jeremy A Syrjanen; Maria Vassilaki; Val J Lowe; Prashanthi Vemuri; Michelle M Mielke; Mary M Machulda; Gorazd B Stokin; Teresa J Christianson; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Yonas E Geda
Journal:  Am J Geriatr Psychiatry       Date:  2020-06-17       Impact factor: 4.105

10.  Distinct Patterns of Brain Atrophy associated with Mild Behavioral Impairment in Cognitively Normal Elderly Adults.

Authors:  Jun Shu; Qiang Qiang; Yuning Yan; Yang Wen; Yiqing Ren; Wenshi Wei; Li Zhang
Journal:  Int J Med Sci       Date:  2021-06-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.